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Editor’s key points
† The authors describe the
presentation and
management of malaria
on the ICU.
† They review the literature
and providemanagement
strategies for dealing with
this life-threatening
condition.
The number of people travelling to malaria-endemic countries continues to increase, and
malaria remains the commonest cause of serious imported infection in non-endemic areas.
Severe malaria, mostly caused by Plasmodium falciparum, often requires intensive care
unit (ICU) admission and can be complicated by cerebral malaria, respiratory distress,
acute kidney injury, bleeding complications, and co-infection. The mortality from imported
malaria remains significant. This article reviews the manifestations, complications and
principles of management of severe malaria as relevant to critical care clinicians, incorporating
recent studies of anti-malarial and adjunctive treatment. Effective management of severe
malaria includes prompt diagnosis and early institution of effective anti-malarial therapy,
recognition of complications, and appropriate supportive management in an ICU. All cases
should be discussed with a specialist unit and transfer of the patient considered.
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The number of people who travel to malaria-endemic areas
continues to increase (Fig. 1).1 Malaria is responsible for the
death of at least three quarters of a million people worldwide
every year2 and is the commonest cause of serious imported
infection in non-endemic areas.3–5 Severe malaria is mostly
caused by Plasmodium falciparum, although other species
can cause severe disease.6 7
Recommendations for themanagementof severe imported
malaria are largely derived from trials in endemic regions and
retrospective series of imported malaria. In spite of advances
in management, the mortality rate of severe malaria remains
10% and data from the UK suggest that the outcome may
beworse for patientsmanaged in centres with less experience
of treating the disease.8 This review is based on recent studies
of anti-malarial and supportive therapies and outlines the
epidemiology of malaria, clinical manifestations, and risk
stratification of severe disease, and provides an update on
the management of patients with imported malaria requiring
intensive care unit (ICU) support.
Epidemiology
Malaria is endemic throughout most of the tropics and sub-
tropics and is one of the commonest causes of febrile illness
in returning travellers.3–5 There were 6749 cases of imported
malaria reported within the European Union in 2010 (0.99
cases per 100 000)9 and 1688 cases reported in the USA (0.55
cases per 100 000).3 In Europe, four countries (France, UK,
Germany, and Italy) account for 80% of all cases. Surveillance
from both Europe and the USA show that most cases of
falciparum malaria are acquired in sub-Saharan Africa.3 10–12
Compared with malaria in endemic settings, where children
are most commonly affected, imported malaria is predomin-
antly a disease of young- and middle-aged adults—the
median age of cases in the UK is 31 years.13
Surveillance data demonstrate that individuals originating
fromendemic regionswho travel to ‘visit friends and relatives’
are more likely to develop malaria than people who travel for
other reasons (relative risk 3.65),5 13 although these indivi-
duals may be at reduced risk of developing severe disease
because of partial immunity.11 14 Anti-malarial chemo-
prophylaxis is veryeffective but surveillance data consistently
demonstrate that most travellers do not take it appropriate-
ly.3 13 15 Reasons for poor adherence include an assumption
of low risk, particularly among individuals who grew up in
endemic regions, and concerns about potential drug side
effects.
Nearly all severe disease is caused by falciparum malaria;
10% of patients with imported falciparum malaria are
reported to develop severe disease.3 16 The case fatality rate
is 1%.3 13 UK surveillance data demonstrate significantly
higher mortality (odds ratio 10.68) in patients aged .65 yr
comparedwith adults aged18–35 yrandamong tourists com-
pared with patients originally from endemic countries (odds
ratio 8.2).8 Death from non-falciparum malaria is extremely
rare with a case fatality rate of 0.05%.8
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Pathophysiology
Malaria is caused by infection with the protozoan parasite Plas-
modiumand is transmittedby femaleAnophelinemosquitoes.17
Four species are classically considered to cause disease
in humans (P. falciparum, Plasmodium vivax, P. ovale, and
P. malariae) although a fifth, P. knowlesi, is now recognized as
a zoonotic cause of malaria in parts of Malaysia.18 After the
bite of an infectedAnophelinemosquito (Fig. 2), the inoculated
sporozoites are taken up by hepatocytes where they mature
over 7–10 days to form schizonts. These then rupture to
release variable numbers of merozoites into the blood. Mero-
zoites rapidly invade erythrocytes, forming trophozoites,
which again mature into schizonts over a period of 24–72 h,
depending on the species. The mature schizonts then rupture
causing haemolysis, releasing further merozoites into the
bloodwhere they invademoreerythrocytes.WithP. falciparum,
each schizont that ruptures releases 16 merozoites into the
blood. Most schizonts adhere to the lining of small blood
vessels in deep tissues, a process known as sequestration.
The presence of schizonts in peripheral blood implies that
the parasitaemia is likely to increase significantly and is itself a
marker of severe disease. Human disease is caused by these
asexual stages. Gametocytes, the sexual stage, develop some
days later and it is these that are taken up by mosquitoes in
endemicareas,wheretheybreedandmultiply inthemid-gut,ul-
timately leading to sprozoites found in themosquitoes’ salivary
glands. Gametocytes are frequently seen on blood films but, by
themselves, are of no clinical significance.19
The incubationperiod for falciparummalaria isusually12–14
days and slightly longer for non-falciparum species. One series
of imported malaria reported a median of 9.5 days (IQR 3–14)
between return from a malaria-endemic area and hospital ad-
mission.11 Progression to severe disease is variable; however,
the largest series of severe importedmalaria found ameandur-
ation of symptoms of 5.5 days before ICU admission.20
Infection with P. falciparum results in the expression of
P. falciparumerythrocytemembraneprotein1 (Pfemp1), an im-
portant virulence factor, on the surface of red blood cells.
Pfemp1 mediates binding of infected red blood cells to endo-
thelial surfaces and sequestration in capillary beds.21 Pfemp1
is encodedby the var familyof genes and theparasite regularly
switches between 60 variants of this gene resulting in
Fig 1 Countries and areas with risk of malaria transmission. Map from WHO International Travel and Health Programme, http://www.who.int/
ith/en/. Reproduced with permission of the World Health Organisation.
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significant antigenic variation and an impaired immune re-
sponse.21 Release of pro-inflammatory cytokines, including
TNF-a and IL-1, in response to infection leads to an
up-regulation of endothelial receptors including Intracellular-
Adhesion Molecule 1 resulting in further sequestration.22 Oc-
clusion of capillary beds leads to microvascular obstruction,
tissue hypoperfusion, and lactic acidosis.23 Capillary seques-
tration also impairs splenic clearance of infected red blood
cells. The severity of disease is associated with both a higher
total body parasite biomass and a higher biomass of seques-
tered parasites.24
Diagnosis
Microscopic examination of a blood film remains the gold
standard for diagnosis of malaria (Fig. 3).26 This allows speci-
ation, quantification of parasitaemia, and detection of other
markers of severity such as the presence of schizonts. In a
non-endemic setting, a parasite count .2% of infected red
cells is usually considered amarker of severe disease although
lower counts do not exclude this.26 27 Both thick and thin films
should be examined. Thick films have a higher sensitivity for
diagnosis while thin films allow more accurate speciation
and quantification of parasitaemia.28 Rapid diagnostic tests
(RDTs) are used in many settings. RDTs detect circulating
parasite-associated proteins and enzymes. Most tests detect
both a pan-species target and a falciparum-specific target.
RDTs allowdiagnosis ofmalariawithout a trainedmicroscopist
but do not usually provide speciation nor quantification of
parasitaemia. As such, these tests should be considered an
adjunct rather than a replacement for blood film analysis.26 27
The use of PCR to diagnose malaria remains a research tool,
but may occasionally be useful, particularly when there is
doubt about the infecting species, for example in the differenti-
ation of P. knowlesii from P. malariae.
Criteria for severe or complicated malaria
Criteria for severe malaria in both endemic and non-endemic
settings have been defined by the World Health Organisation
(WHO) (Table 1).29 In imported malaria, the commonest
reasons for ICU admission are cerebral malaria, acute respira-
tory distress syndrome (ARDS), and acute kidney injury (AKI),
either alone or in combination.11 20 30 As parasitized erythro-
cytes sequester in deep capillaries, the peripheral parasitaemia
may not accurately reflect the true burden of infection.
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Fig 2 Life cycle of Plasmodium. Image from the Centers for Disease Control and Prevention (www.cdc.gov). Image produced by CDC—DPDx/Alex-
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Important information Triage
Key points in history and examination—no symptoms or signs can accurately predict malaria
Urgent investigations—all patients should have:
Blood tests show
Falciparum malaria
Complicated malaria=one or more of:
Admit all case to hospital
Assess severity on admission
No evidence of malariaNon-falciparum malaria
Non-falciparum antimalarials
Falciparum antimalarials Essentials features of general management Falciparum antimalarials
Uncomplicated:
Severe malaria Complicated or if patient isvomiting:
If falciparum malaria is confirmed
Expert advice
Useful information
Early diagnosis and assessment of severity
is vital to avoid malaria deaths
Malaria occurs in the tropics and sub-tropics All febrile or ill patients with a history of travel to a malaria
area in the prior 6 months should be assesssed urgently
(Incubation for non-falciparum infection may occasionally be
greater than 6 months)
Local infectious disease unit or
Liverpool   0151 706 2000
London      0845 155 5000
Ask for duty tropical doctor
British National Formulary
UK malaria treatment guidelines:
Lalloo DG et al. J Infect 2007; 50: 111–21
from www.hpa.org.uk or
www.britishinfectionsociety.org
For those within 3 weeks of return, discuss infection
control requirements [e.g. viral haemorrhagic fever (VHF),
avian influenza or SARS] with the duty microbiologist but
do NOT delay blood film
Adherence to chemoprophylaxis does not
exclude malaria
Patients with malaria may deteriorate rapidly
Symptoms are non-specific, but may include: fever/sweats/chills, malaise,
myalgia, headache, diarrhoea, cough, jaundice, confusion, and seizures
Consider what malaria prophylaxis was taken (i.e. drug, dose and adherence):
Correct prophylaxis with full adherence does not exclude malaria
Consider other travel-related infections: for example typhoid fever, hepatilis, dengue
fever, avian influenza, SARS, HIV, meningitis/encephalitis, and VHF
Examination findings are non-specific
Consider country of travel, including stopvers, and date of return;
falciparum malaria is most likely to occur within 3 months of return, but this
may be longer in those who have taken chemoprophylaxis or partial
treatment. The incubation period for malaria is at least 6 days
Thick and thin blood films and malaria rapid
antigen tests. Send to laboratory
immediately and ask for a result within 
1 h
Blood culture(s) for typhoid other,
bacteraemia, or both
Ask the laboratory to estimate the parasite count—
that is % of RBCs parasitised
Clotting screen, arterial blood gases, and 12-lead ECG
are required in complicated infection (see below)
Do a pregnancy test if there is a possibility of
pregnancy; pregnant women are at higher risk of
severe malaria
Urine dipstick (for haemoglobinuria) and
culture, if the patient has diarrhoea, send
faeces for microscopy and culture
Chest radiograph to exclude community-
acquired pneumonia
Full blood count (FBC) for thrombocytopenia,
urea & electrolytes (U&Es), liver function
tests (LFTs), and blood glucose
Vivax Outpatient therapy
usually appropriate
depending on clinical
judgement
Chloroquine (base) 600 mg followed by
300 mg at 6, 24, and 48 h. In vivax
and ovale after treatment of acute
infection use primaquine (30 mg
base/day for vivax, 15 mg/day for
ovale) for 14 days to eradicate liver
parasites; G6PD must be measured
before primaquine is given—seek
expert advice if low
Impaired consciousness (measure GCS and MSQ) or seizures
check blood glucose urgently
Hypoglycaemia
Parasite count >2% (lower counts do not exclude severe malaria)
Haemoglobin <8 g/dL
Spontaneous bleeding/disseminated intravascular coagulation
Haemoglobinuria (without G6PD deficiency)
Renal impairment or electrolyte/acid—base disturbance (pH <7.3)
Pulmonary oedema or adult respiratory distress syndrome
Shock (algid malaria) may be due to Gram negative becteraemia 
Falciparum
Mixed infection
Species not characterised A single negative film and/or antigen
test does not exclude malaria
Stop prophylaxis until malaria excluded
Empirical therapy for malaria should be
avoided unless the patient is severely ill.
Seek expert advice before commencing
this (see contact numbers above)
Blood films daily for 2 more days
Malaria is unlikely with three negative
blood films. Consider other travel and
non-travel illness
Finish chemoprophylaxis
K210
February 2007
Health
Protection
Agency
BRITISH
INFECTION
SOCIETY
Ovale
Malariae
All cases should be discussed with a
specialist with current experience of
managing malaria
Natify all cases to the local health protection
unit, send blood films to reference
laboratories
OR
OR
(a) Oral quinine 600 mg/8h plus
 doxycycline 200 mg daily (or
 clindamycin 450 mg/8 h) for 7 days 
Commence antimalarials immediately (see boxes)
EITHER Quinine 20 mg/kg loading dose (no
loading dose if patient taking quinine or
mefloquine already) as IVI in 5% dextrose
over 4 h and then 10 mg/kg as IVI over 4 h
every 8 h plus oral doxycycline 200 mg daily
for 7 days (in pregnancy, use IV/oral
clindamycin 450 mg/8 h). Max quinine
dose 1.4 g
OR If available, artesunate intravenously
2.4 mg/kg at 0, 12, and 24 h then daily to
complete a course of 7 days plus
doxycycline or clindamycin as above
When patient is stable and able to swallow,
switch to oral quinine 600 mg/8 h plus
doxycycline 200 mg daily (or clindamycin
450 mg/8 h) to complete 7 days
Consider admission to high dependency/intensive care
Seek early expert advice from an infection or tropical unit
Oxygen therapy
Monitor blood glucose regularly (especially during i.v. quinine)
ECG monitoring (especially during i.v. quinine)
Four-hourly observations until stable: that is pulse, temperature, BP,
RR, SaO2, urine output, and GCS. Regular medical review
until stable
Repeat FBC, clotting, U&Es, LFTs, and parasite count daily
In shock, treat for Gram negative bacteraemia
Careful fluid balance (abserve JVP, lying/sitting BP and urine
output). Avoid hypovolaemia. Ocer-hydration may induce
pulmonary oedema; consider CVP monitoring
(b) Malarone® : four ‘standard’ tablets daily
 for 3 days
(c) Riamet® : if weight >35 kg, four tablets
 then 4 tablets at 8, 24, 36, 48, and
 60 h
Fig 3 Health Protection Agency and British Infection Associated Algorithm for Initial Assessment and Management of Malaria in Adults.25
& Crown copyright. Reproduced with permission of Public Health England.
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Hyperparasitaemia is therefore not a consistent finding in
patientswith severemalaria, andmay not be a feature in a sub-
stantial proportion of patients requiring ICU admission.11
Differential diagnosis
The differential diagnosis of severe malaria is broad and
varies depending on the patient’s travel history.31 Major con-
siderations include the common causes of community-
acquired Gram-positive and Gram-negative bacterial sepsis,
enteric fever, severe rickettsial infections, and leptospirosis,
and also arboviral infections (including dengue fever) and the
viral haemorrhagic fevers. Consultation with a specialist is
recommended if there is any doubt as to the diagnoses or in
anypatient considered tobeat riskof viral haemorrhagic fever.
Anti-malarial drugs
Since the emergence of chloroquine resistance in the 1970s,
parenteral quinine has been the mainstay of treatment for
severe malaria (Table 2). The commonest dose-related side
effect of quinine is cinchonism, which comprises tinnitus,
blurred vision, reversible hearing loss, headache, and nausea.
Quinine may also cause hypoglycaemia and prolongation of
the QTc interval on an electroencephalography (ECG) necessi-
tating regularmonitoring, but is usuallywell tolerated. Artemi-
sinins, derived fromtheChineseherbqinghausuorwormwood,
have been used by Chinese traditional healers for many years
but have become available to western practioners only in
recent years.
The artemisinin derivative artesunate has recently been
shown to be more effective than quinine for the treatment of
severe falciparummalaria in two large randomized trials.32 33
The SEAQUAMAT study randomized 1461 mostly adult pa-
tients with severe malaria in South and South-East Asia,
and showed a significant reduction in mortality in patients
treated with artesunate compared with quinine (15% vs 22%,
P¼0.0002).32 The subsequent AQUAMAT study randomized
5425 children (,15 years) with severe malaria across eleven
countries in sub-SaharanAfricaandagain showedasignificant
reduction in mortality with artesunate (8.5% vs 10.9% for
quinine, P¼0.0022).33 Routine monitoring for hypoglycaemia
and QTprolongation are unnecessary if an artemisinin deriva-
tive is used. Although extremely effective in treating malaria,
they cannot be used as single agents as the rate of recrudes-
cent infection is very high.
Availability of artesunate has been limited in many coun-
tries, including the UK, as the drug is not licenced and is only
available on a named patient basis.34 Because of this, paren-
teral artesunate is only available in relatively few specialist
centres. Treatment with quinine should not be delayed while
artesunate isobtained. If there is anydoubtabout the infecting
species, then treatment for falciparum should be prescribed.
Artemisinin combination treatments (ACTs), which combine
an artemisinin with another effective anti-malarial drug, are
nowrecommendedby theWHOasfirst-line treatment for non-
severe malaria27 and should be used after initial treatment
with parental artesunate. Early liaisonwith a specialist tropical
medicine or infectious diseases unit is essential to ensure ap-
propriate treatment as soon as possible. The treatment strat-
egy used at the Hospital for Tropical Diseases, London, UK, is
outlined in Table 2.
Resistance to quinine has been widely reported from
South-East Asia and occasionally from sub-Saharan Africa.35
However, in the context of malaria, resistance is a relative
rather than an absolute phenomenon. Partial artemisinin re-
sistancehasalsobeenseen inSouth-EastAsia, especiallyCam-
bodia, and Thailand36–38 and results in a decreased rate of
clearance of asexual parasites from the blood. Treatment
failure with ACTs has not yet been reported, but its develop-
ment and the potential for artemisinin resistance spreading
to Africa is a major concern.
Exchange transfusion
Several anecdotal reports and some case series have sup-
ported the use of exchange transfusion in severe malaria, es-
pecially in patients with high parasitaemia; it continues to be
recommended in some national guidelines.26 The rationale is
that exchange transfusion removes both infected red cells,
lowering parasite burden and parasite-derived antigen load,
and circulating pro-inflammatory cytokines. A recent report
from a single-centre reported no deaths among 25 patients
who had an exchange performed.39 However, ameta-analysis
in 2002 found only eight quasi-experimental studies of the ef-
ficacy of exchange transfusion and demonstrated no overall
survival benefit, a finding echoed in a recent study of US
patients;40 the WHO states that no recommendation regard-
ing exchange transfusion is possible based on the paucity of
current evidence.27 41 At our centre, exchange transfusion
Table 1 Criteria for severemalaria. Adapted fromWHO Guidelines
for the treatment of malaria, 2nd Edn.27 http://www.who.int/
malaria/publications/atoz/9789241547925/en/index.html.
Reproduced with permission of the World Health Organisation
Clinical features of severe falciparum infection
Cerebral malaria as characterized by impaired consciousness
or coma, convulsions, or both
Acute respiratory distress syndrome
Circulatory collapse
Jaundice in the setting of other organ dysfunction
Haemoglobinuria
Abnormal spontaneous bleeding
Laboratory features of severe falciparum infection
Hypoglycaemia [,2.2 mmol litre21 (,40 mg dl21)]
Severe anaemia (Hb ,5 g dl21, packed cell volume ,15%)
Metabolic acidosis (plasma bicarbonate ,15 mmol litre21 or
pH ,7.35)
Hyperparasitaemia (.2%/100 000 ml21 in low-intensity
transmission areas or .5% or 250 000 ml21 in areas of high
stable malaria transmission intensity)
Hyperlactataemia (lactate .5 mmol litre21)
Acute kidney injury (serum creatinine .265 mmol litre21).
BJA Marks et al.
914
has not been used since the introduction of artemisinin-based
therapy for all patients with severe malaria.
Fluids and cardiac function
The traditional adage is that patients with severe malaria
should be managed with relatively restricted fluid volumes
because of concerns about the risk of capillary leak and lung
and cerebral oedema. This practice is supported by the move-
ment in critical care to a more fluid restrictive practice in
patientswith acute lung injury (ALI).42 However, this restrictive
fluid regimen commences only after initial resuscitation has
been completed. No large trials have assessed fluid resuscita-
tion strategies in patients with severe malaria in a developed
world ICU setting; current data are derived only from trials in
endemic areas and from small physiological studies.
Thefluidexpansionassupportive therapystudyrandomized
3141 African children presenting with severe febrile illness to
maintenancefluidswithorwithoutbolusesofeithercrystalloid
(0.9% saline) or colloid (5% human albumin solution).43
Malariawas the reason for admission in 57% of these children.
The trial was stopped early because of a significant increase in
mortality in both groups who received fluid boluses compared
with the group receivingmaintenance fluids only (4weekmor-
tality 8.7% vs 12.0% and 12.2%, P¼0.004 for comparison of
maintenance with bolus). In a post hoc analysis, there was an
increase in terminal cardiovascular events related to fluid re-
suscitation.44 There were no differences in mortality between
the sub-groups of children with malarial and bacterial infec-
tions. There are obvious limitations in applying these findings
to critical care settings in the developed world as the children
couldnotbeofferedmechanicalventilation, renal replacement
therapy, nor inotropic support. Furthermore, time to hospital
presentation, while not formally measured, was likely to be
significantly longer than in a developed world setting, so the
potential risk of an exaggerated reperfusion injury after ag-
gressive resuscitation cannot be discounted.
Although not considered a traditional manifestation of
severe malaria, there is emerging evidence that cardiac dys-
function may complicate severe disease. A number of studies
have found evidence of increased circulating levels of cardiac
enzymes including BNP in individuals with severe malaria.45–47
Intravascular haemolysis as a result of severe malaria has
been shown in one small study to result in decreased levels
of nitric oxide,47 increased pulmonary pressures, and myo-
cardial wall stress. Further studies to understand the clini-
cal importance of cardiac dysfunction in severe malaria are
warranted.
Previous studies have demonstrated that traditional mar-
kers of fluid balance correlate poorly with acid–base status
and respiratory function.48 The argument against aggressive
fluid loading is strengthened by recent data on the physiol-
ogical response of 28 adult ICU patients with severe malaria
to fluid expansion guided by invasive cardiac monitoring.23
Despite trans-pulmonary thermodilution (PiCCO)guidedthera-
py, acid–base status deteriorated in 68% and no improve-
ment in renal function was observed after volume expansion.
Significant increases in extravascular lung water occurred in
17 of 22 (77%) patients who were liberally resuscitated, with
eight developing frank pulmonary oedema despite being
hypo- or euvolaemic. Five patients died, all ofwhomdeveloped
pulmonary oedema. The authors found that the degree of lac-
tataemia correlatedwith the degree of parasitemicrovascular
sequestration, but not with hypovolaemia.
Table 2 Anti-malarial therapyat theHospital for TropicalDiseases. TheHospital for TropicalDiseases’ treatmentguidelinesarebasedonpartof the
UK malaria treatment guidelines26 but have been updated to reflect the growing importance of artesunate since the guidelines were published.
*Quinine therapy should not be delayed if artesunate is not immediately available. Patients do not require treatment with both artesunate and
quinine. Once the first dose of artesunate has been given, quinine can be stopped
Route of administration Quinine Artesunate*
i.v. i.v.
Dosing 20 mg kg21 loading dose (max 1400 mg)
Subsequently 10 mg kg21 (max 700 mg) given 8 hourly
2.4 mg kg21 at 0, 12, and 24 h and then
once daily
Side effects Cinchonism—tinnitus, visual blurring, and nausea.
Reversible and not an indication to stop quinine
Hypoglycaemia
Prolongation of the QT interval
Normally well tolerated although
posttreatment haemolysis is recognized
Monitoring Capillary blood sugar 2–4 h
ECG monitoring of QTc
Continuous cardiac monitoring advised in patients with
underlying cardiac disease
Not required
Follow-on therapy
Therapy can be switched once the patient is
improving clinically, the parasite count is
,2%,
and theycan tolerateoralmedication.Discuss
with an expert
Oral quinine 10mg kg21 (max 700mg) TDS to complete
7 days total course with either
Doxycycline 200 mg for 1 week or
Clindamycin 450 mg TDS for 1 week
Doxycycline of clindamycin can be given either
simultaneously (with both i.v./oral quinine) or after
completion of quinine therapy
Artemether/Lumefantrine (Riamet,
Co-Artem) four tablets at 0, 8, 24, 36, 48,
and 60 h.
Quinine (10 mg kg21 max 700 mg) with
doxycycline or clindamycin for a total of
7 days
Atovaquone/Proguanil (Malarone) four
tablets OD for 3 days
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It would appear that, in the absence of prospective, rando-
mized trial data, liberal fluid therapy is best avoided in the
context of severe malaria. Because of the propensity of these
patients towards capillary leak and thus a greater risk of
ARDS and cerebral oedema, our own management approach
is to target significant hypovolaemia with concurrent tissue
hypoperfusion, that is, clinical markers of organ dysfunction
(e.g. oliguria) with biochemical markers (e.g. lactate and
central venous oxygen saturation). Fluid loading is guided by
a goal-directed algorithm using both the stroke volume re-
sponse to a fluid challenge (measured by minimally invasive
oesophageal Doppler) and markers of tissue perfusion as
therapeutic endpoints. Otherwise, fluid balance is kept
neutral, in line with studies in critically ill patients showing a
strong association between positive fluid balance and worse
outcomes.49 Where vasopressor, inotrope, or both require-
ments persist, we maintain an acceptable cardiac output,
avoiding fluid overload but targeting tissue perfusion and
have a low threshold for diuresis in the haemodynamically
stable patient in the postinflammatory phase of illness.
Respiratory manifestations
TheWHO defines respiratorymanifestations of severemalaria
in termsofdeepbreathing, respiratorydistress, andpulmonary
oedema.27 Cough is a common symptom,50 and tachypnoea
may be caused by fever, anaemia, and a metabolic acidosis,
and also primary lung pathology such as the ARDS and pneu-
monia. ARDS has clear diagnostic criteria that have been re-
cently redefined,51 with the previous clinical distinction
between ALI and ARDS being replaced by mild, moderate,
and severe levels of ARDS. This condition is more common
among adults than children.52 The reported incidence of ‘re-
spiratory distress’ in severe malaria varies between 2 and
30%, with differences in definitions accounting for some
of this variation.10–12 20 52–54 ARDS and respiratory distress
are poor prognostic signs in both endemic and imported
malaria.20 55 56
The mechanisms underlying ARDS are not entirely under-
stood, but likely causes include endothelial dysfunction and
altered capillary permeability because of parasitized erythro-
cyte adherence and sequestration and exaggerated host
immune and inflammatory responses, particularly TNF-a,
IL-1, IL-6, and IL-8.57 58 However, ARDS can develop after ap-
parently successful treatment and after the disappearance
of parasites from the blood.11 53 In these cases, ARDS may
reflect persistence of inflammatory cytokines in the absence
of any infected erythrocytes. There is emerging evidence that
free parasite antigens may persist after treatment suggesting
that these may represent a potential on-going stimuli for in-
flammation.52 Concurrent bacterial pneumonia and cardio-
genic pulmonary oedema (which may be iatrogenic, the
result of renal failure, severe anaemia, or heart failure related
to a sepsis-induced myocardial depression) are other import-
ant causes of respiratory distress.
As there are no specific trials addressing ARDS treatment in
malaria, strategies are based on evidence-based ARDS
management, including theuseof lowtidal volume ‘protective’
ventilation and moderate levels of PEEP.59–62 Fluid balance is
kept neutral, or negative if the patient is considered to be
volume overloaded. Cerebral oedema and raised intracranial
pressureassociatedwithcerebralmalariamay limit permissive
hypercapnia and the use of high PEEP strategies; however,
pragmatic clinical decision-making should be used.63 Success-
ful use of extracorporealmembraneoxygenation for severe re-
spiratory failure has been reported in malaria.12 64 Bacterial
co-infection is relativelycommonsuggesting thata lowthresh-
old for starting antibiotics, when supported by clinical and la-
boratory investigations, may be appropriate.11 20 30
Hypoglycaemia
Hypoglycaemia, defined as blood glucose values ,2.2 mmol
litre21 (,40 mg dl21),27 is a common complication of ma-
laria and can be a marker of severe disease, particularly in
children.65 66 Case series of imported malaria report a preva-
lenceofhypoglycaemiabetween1and20%atadmission,with
a higher rate among those who die.10–12 20 54 The pathogen-
esis is poorly understood but is thought to be related both to
parasite glucose consumption and to impaired host gluconeo-
genesis rather than to malnutrition or hyper-insulinaemia.67
Hypoglycaemia may be exacerbated by parenteral quinine
(an insulin secretagogue). A meta-analysis reported a signifi-
cantly lower incidenceduring treatmentwithartemisinins com-
pared with quinine [combined HR 0.55 (95% CI 0.41–0.74)].68
Clinical features include a reduced level of consciousness and
seizures. Blood glucose should be routinely and regularly
assessed and monitored, especially during treatment with
quinine. Earlyenteral feedinghas beenestablishedas beneficial
in a wide range of patients requiring intensive care, and may
mitigate against hypoglycaemia in severe malaria.69 70
Neurological involvement
Cerebral malaria is strictly defined as coma [Glasgow Coma
Score (GCS) ,9] in a patient with malaria in whom other aeti-
ologies have been excluded.29 In clinical practice, a decrease
in GCS ,11 or the occurrence of seizures should be taken to
represent cerebral malaria once hypoglycaemia and other po-
tential causes of reduced consciousness have been excluded.
As with respiratory distress, cerebral malaria is associated
with worse outcomes.71 The pathogenesis remains incom-
pletely understood.72 Electroencephalography has previously
found sub-clinical seizure activity in a proportion of patients
with cerebral malaria73 which prompted three anti-epileptic
trials.74–76 However, despite a reduction in seizure frequency,
mortality was increased in patients receiving routine anti-
convulsant therapy with phenobarbital.77 This increased mor-
tality ispostulated tooccurasa resultof respiratorydepression.
The extent towhich these findings can be generalized to other
classes of anti-epileptics, in particular those that cause less re-
spiratory depression, is unknown. In view of these findings,
there is currently no role for routine EEG monitoring and the
use of anti-epileptics in patients with cerebral malaria should
be limited to those with clinically overt seizure activity.
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Cerebral oedema is a well-recognized component of cere-
bral malaria and strategies to reduce this have been assessed
in controlled trials. Warrell and colleagues78 randomized
patients with cerebral malaria to receive either dexametha-
sone or placebo. Mortality did not differ between the two
groups (P¼0.8) but comawas prolonged in thosewho received
dexamethasone [63.2 (5.9) h vs 47.4 (3.2) h, P¼0.02]. This
finding is consistent with other studies of corticosteroids in
cerebral oedema because of other aetiologies such as head
injury.79 Complications, including gastrointestinal bleeding
and pneumonia, were also more common in patients receiv-
ing dexamethasone (P¼0.004). Mohanty and colleagues80
randomized 61 adult patients with cerebral malaria and CT-
confirmed cerebral oedema to adjunctive treatment with
mannitol. There was a non-significant trend towards a higher
mortality in those receiving mannitol (30% vs 13%, HR 2.4
95% CI 0.8–7.3, P¼0.11). Mannitol was also associated with
a significant increase in the duration of coma (90 h compared
with 32 h with placebo, P¼0.02). Other adjunctive treatments
including N-acetyl cysteine, heparin, aspirin, deferoxamine,
anti-TNF therapy, and pentoxifylline have all been trialled but
none has been shown to be of benefit.81–85 No adjunctive
treatments are currently recommended for cerebral malaria.
Acute kidney injury
AKI in malaria is usually caused by P. falciparum, although it
has been reported with other species.86 87 The WHO uses a
serumcreatinine of.265mmol litre21 (or≥3mgdl21) as a cri-
terion for severe malaria,27 although this definition is at vari-
ance with commonly applied definitions of AKI.88 AKI is
particularly common among individuals who did not grow up
in endemic regions, suggesting that it may be more common
in the malaria-naı¨ve.89–91 The incidence of AKI in severe
malaria varies from 1 to 5% in endemic areas,91 but the rate
of AKI is much higher in series of imported malaria (ranging
from 23 to .50%).10–12 20 53 54 Cytoadherence of parasitized
erythrocytes to glomerularand tubular vascular beds, cytokine
release, immune complex deposition, hypovolaemia, and
haemolysis may all be contributory.57 91–93 Histopathological
findingsofAKI inseveremalaria includeacutetubularnecrosis,
interstitial nephritis, and glomerulonephritis, although tubular
changes are the most common findings.89
All patients with falciparummalaria should be screened for
AKI,whichmaynotdevelopuntil severaldaysafter theonsetof
fever and can be non-oliguric.91 Management is supportive
with maintenance of fluid balance and electrolytes and renal
replacement therapy as indicated. Trials of both dopamine
and epinephrine have been performed in severe malaria, but
neither has been shown to improve renal oxygen metabolism
nor function.94 Artemisinin doses do not need adjusting in
AKI; however, quinine may accumulate, so doses should be
reduced by one-third after 48 h of established renal failure,
unless renal replacement therapy has been initiated.27 The
prognosis of AKI associated with severe malaria is usually
good, and it inevitably resolves in days to weeks. A recent UK
series found that even those patients with persisting renal
impairment at discharge from ICU ultimately recovered their
renal function.11
Co-infection
In endemic areas, concurrent community-acquired Gram-
negative bacteraemia, in particular with non-typhoidal Sal-
monellae, has been shown to occur in 5–12% of children
with malaria.95–97 Recent studies have suggested that
almost two-thirds of cases of community bacteraemia in
endemic regions may be the result of malaria. Furthermore,
invasive bacterial disease is associated with a worse progno-
sis.95–97 One proposed mechanism is induction of heme
oxygenase-1, which mediates tolerance to malaria-induced
haemolysis, resulting in reduced resistance to infection with
non-typhoidal Salmonellae.98 However, few data are available
on the frequency of bacteraemia in adult patients or returned
travellers.
Rates of microbiologically confirmed community-acquired
bacterial infections have been reported as 5–10% in patients
with imported malaria requiring ICU admission.11 20 30 Pneu-
moniawas the commonest co-infection. Community-acquired
bacteraemia has been reported in 1.5–3% of cases requiring
ICU admission. However, these studies were all retrospective
and a failure to take blood cultures before antibiotics were
administered may have resulted in an under-estimate of the
true frequency of bacteraemia. The possibility of co-infection
in returning travellers is an additional reason for early liaison
with a specialist unit. High rates of co-infection with HIV have
also been reported in some series.11
The use of empiric antibiotics remains controversial, but
bacterial co-infection should be suspected in any patient
with focal signs or symptomsof sepsis or significant neutrophi-
lia. In such cases, blood cultures should be taken and broad-
spectrum antibiotics commenced,27 albeit de-escalating
quickly or stopping treatment if bacterial infection is subse-
quently not confirmed. Clinicians should also remain alert to
the possibility of nosocomial infection. Ventilator-associated
pneumonia and catheter-related sepsis are well recognized
in this setting and frequently contribute to poor outcomes
despite adequate anti-malarial treatment.11 20
Anaemia and coagulopathy
Malarial anaemia is caused by a combination of haemoly-
sis, dyserythropoiesis, and removal of infected erythrocytes
from the circulation by the spleen. Parasite antigens, antibody
activation, and subtle alterations in red cell membranes may
also result in a similar fate for uninfected cells.99 WHO
defines severe anaemia as a haemoglobin concentration of
,5 g dl21.27 However, severe malarial anaemia is mostly
seen in endemic areas, especially among children and preg-
nant women, and is likely to be multifactorial.99 Only one
series of imported malaria reported patients presenting with
severe anaemia as defined by the WHO.20 Transfusion is
recommended in severe anaemia, although no specific stud-
ies have addressed transfusion targets in malaria. Current
critical care practice supports a restrictive use of red cell
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transfusions, and this is supported byWHO recommendations
of a haemoglobin threshold of 7 g dl21, taking into account in-
dividual clinical circumstances.27 100 101
Clinically apparent abnormal bleeding and coagulopathy
is commonly seen in severe imported malaria, with a re-
ported frequency ranging from ,5%20 54 102 103 to 20% or
more.10–12 53 Profound thrombocytopenia is common in both
severe and non-severe falciparum malaria and is probably
caused by increased platelet consumption, sequestration
within the spleen, or both. Disseminated intravascular co-
agulation, which occurs in about 5–10% of severe imported
malaria, should be treated conventionally with transfusion of
screened blood products (whole blood, cryoprecipitate, fresh
frozen plasma, and platelets) and guided by haematological
expertise, but there isnoevidence to support empirical platelet
transfusion.11 12 20
Prognosis
Mortality fromseveremalariavariesenormouslybysettingand
clinical context. Amortalityof.30%has been reported in chil-
drenwith respiratorydistressand impairedconsciousness.55 In
theUK, the overall case fatality rate from falciparummalaria is
1%.8 Increased age and management at a centre with less
experience of managing malaria have both been identified as
risk factors for increased mortality, while individuals born in
endemic countries hada lowermortality.8 In studies of artemi-
sinins, overall mortality was 10–19%.32 33 Case series of
patients with imported malaria requiring ICU admission have
reported mortality rates between 5 and 29%.11 104 Older age,
reduced GCS, and higher parasitaemia at ICU admission were
significantly associated with an increased mortality in the
largest cohort,20 albeit not consistently replicated in other
studies.11 30
Risk stratification
Two scoring systems have been proposed for the stratification
ofadultpatientswithseveremalaria.105 106Hansonandcollea-
gues105derivedasimplescore (coma–acidosis–malaria score)
using arterial base deficit and GCS derived from SEAQUAMAT
trial data.32 Patients score 0–2 points for their GCS level and
0–2 points for base deficit. A total score of,2 accurately iden-
tified patients who survived (positive predictive value 95.8%).
However, the positive predictive value of CAM scores for
mortality is more limited.
Mishra and colleagues106 derived the malaria score for
adults (MSA) based on the presence or absence of severe
anaemia (1 point), AKI (2 points), respiratory distress (3
points), and cerebral malaria (4 points). Mortality increased
steadily with an increasing MSA, from 2% for MSA scores of
0–2 to 90% for those scoring ≥7. Taking MSA scores of 5 as a
cut-off, they reported a sensitivity of 89.9% for mortality and
a positive predictive value of 94.1%. As with the CAM score,
patients with imported malaria having a low score (,5) had
good predictive power for survival, whereas high scores had a
limited predictive power for death.11 The utility of both these
scores is likely to vary significantly between resource-rich and
resource-scarce settings.
Conclusions
Rates of international travel continue to increase and the
‘febrile returned traveller’ is an increasingly common clinical
problem. Malaria remains the most important cause of
imported fever and cases requiring ICU admission continue
to be associated with a high mortality. While there have been
significant advances inour understandingof themanagement
of malaria in the last decade, high-quality data to guide man-
agement of imported malaria remain scarce, with most
derived from endemic settings or retrospective series. The
emergence of artemisinin-based therapy has translated into
a significant improvement in outcomes in endemic countries
and is likely to improve outcomes in imported malaria in the
future. Despite numerous studies, no adjunctive therapy has
been shown yet to confer a survival advantage and several
have proved harmful. ICU management remains supportive
and improvedoutcomesmaybeattributablemore toadvances
in multi-disciplinary team working, mechanical ventilation
strategies, careful fluid management, and infection control.
Despite these advances, the mortality from imported malaria
remains significant; all cases should be discussed with a spe-
cialist unit and transfer of the patient considered.
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